2017
DOI: 10.2147/ijn.s127329
|View full text |Cite
|
Sign up to set email alerts
|

A review on current nanomaterials and their drug conjugate for targeted breast cancer treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
58
0
1

Year Published

2017
2017
2024
2024

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 83 publications
(59 citation statements)
references
References 84 publications
(65 reference statements)
0
58
0
1
Order By: Relevance
“…Several approaches have been investigated with regard to possible ways to improve cancer therapy. In the last decade, the most important archetype improvement in drug carriage was heralded by the use of nanomaterials (De Jong and Borm, 2008;Lee et al, 2017). Nanotechnology offers a variety of possibilities, including enhancement of drug delivery, facilitation of diagnostics, bioimaging, active implants, and direct therapeutic effects (Nune et al, 2009;Tomisa et al, 2011;Kadam et al, 2012;Laroui et al, 2013;Gmeiner and Ghosh, 2015).…”
Section: Introductionmentioning
confidence: 99%
“…Several approaches have been investigated with regard to possible ways to improve cancer therapy. In the last decade, the most important archetype improvement in drug carriage was heralded by the use of nanomaterials (De Jong and Borm, 2008;Lee et al, 2017). Nanotechnology offers a variety of possibilities, including enhancement of drug delivery, facilitation of diagnostics, bioimaging, active implants, and direct therapeutic effects (Nune et al, 2009;Tomisa et al, 2011;Kadam et al, 2012;Laroui et al, 2013;Gmeiner and Ghosh, 2015).…”
Section: Introductionmentioning
confidence: 99%
“…Carbon nanotubes (CNTs), which are one of the most widely researched carbon nanomaterials for cancer therapy, have been reported to enhance the efficacy of cancer drugs such as doxorubicin by suppressing the drug’s toxic side effects and by bypassing chemoresistance. Despite these advantages, CNTs can induce undesirable cytotoxic side effects, and the lack of long-term studies on their toxicity in humans has prevented the study of this nanocarrier in the clinical setting [100]. However, a number of clinical studies have been conducted with more biocompatible carbon nanomaterials for cancer therapy, such as activated carbon nanoparticles, which were evaluated as nanocarriers for methotrexate in a 1996 clinical study for the treatment of gastric and esophageal cancers [101].…”
Section: Delivery Of Therapeuticsmentioning
confidence: 99%
“…Качественный анализ взаимодействия проводили путем измерения оптической плотности суспензий на спектрофотометре Экрос ПЭ-5400ВИ на длине волны 315 нм, соответствующей максимум поглощения «Амоксициллина». Полученные изотермы соответствуют адсорбции типа IV, ассоциирующейся с капиллярной конденсацией в мезопорах, что являются одними из определяющих характеристик загрузочной способности НП в качестве системы доставки [10], поэтому для дальнейших экспериментов использовался образец с концентрацией допанта 3 %, имеющий максимальные размер и объем пор.…”
Section: Siounclassified